Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. - Wikidata - wikimedia - TriplyDB

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

http://www.wikidata.org/entity/Q34810176

about

Targeting the RAS oncogene.The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian Functions Role of Akt signaling in resistance to DNA-targeted therapy Chemoresistance and targeted therapies in ovarian and endometrial cancers High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.PAK1 mediates resistance to PI3K inhibition in lymphomas.p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation.Multiple signal pathways in obesity-associated cancer.Glial progenitors as targets for transformation in glioma.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.Screening cell mechanotype by parallel microfiltration Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer.p110δ PI3 kinase pathway: emerging roles in cancer.Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives (18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.mTOR pathway in colorectal cancer: an update.Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs.

P2860

Q27687198-4614EA3D-6EE1-480B-B0D7-D807B9F821F6 Q28066925-B0DBB21A-1F1B-493A-8056-A059BE7E928B Q28066950-11A0ECD6-2314-42D2-AB23-3BF08B407A4F Q28073246-EC7D02E8-6423-4D81-BFC6-E16C45DBED31 Q28487341-82F25593-D2BC-4150-BC2B-DD8EEF529D53 Q28573157-426EFD77-C13A-46E8-AC82-4D7648F11DEA Q30881669-8A698DEC-F295-4758-8666-DD23A3C40020 Q33934922-24E2770C-6238-4CE9-AE8A-66FC517CA157 Q34038031-0CCDBB87-F702-4B17-916B-B2061702EA8C Q34226670-11902BF6-A54B-46AE-B8D2-B898D3DB0D01 Q34450398-A9CAC0A9-445E-45B5-BFB7-F52DFAE170F2 Q34539577-B4D82B3A-FD71-4293-A4BB-1675AECC38D8 Q34619266-CB7E8E7A-7748-4FFE-9A13-0FD66FEFD146 Q34633750-173F375C-D58A-4B0E-AD1C-A3748F793C2A Q34735661-1520551E-0E7E-4A6A-AD0A-65E24B4CA54F Q35070685-5946F5A1-CCDE-4E6F-B8E6-A83549B73D37 Q35071010-BF77D18E-78FB-46A2-8E34-FAFCC6503EDE Q35589601-A52B9EA3-56E9-4B51-A452-013B9F33FE9F Q35852880-1E6ED71E-9752-429F-8CE6-EDE191A9B3C3 Q35948581-E4E39AA1-AD2A-4498-9E39-7DA04242699C Q35955302-CE65A640-EC40-4EE5-AB8D-2C156D98E3D0 Q36028196-AA0575F8-018F-43F8-B011-926F18BC45C8 Q36291106-DDBCBE43-E969-44FE-B084-B10AAACED2E0 Q36340162-26BA9C7A-7A9E-4C23-9429-3E1976F41FE6 Q36588615-CDB6EC53-498D-4956-97A9-1278E7A816D2 Q36647928-7149CFAC-5236-4DD0-880C-C0D69AC2368D Q36689033-F8A9B780-A49E-4633-ACFA-23DC5966309D Q36781854-9BF2F55B-EC44-462A-844A-0D19F7215D8D Q36820568-6510A4D3-4CC2-4586-8D0F-6A45F012689B Q37004340-D534C882-BF36-4AD6-A1DE-E643DF1659B3 Q37132788-DEF68C60-336D-4668-9C08-27DE6EFA177B Q37236032-E9678220-A868-4E9F-A45F-5D51160D5F83 Q37350230-0A3DB2B9-0991-4FEB-9ABE-2E19D79C7910 Q37421296-9E834A1D-D09A-48C9-B29C-66ADDAC1AB2B Q37626600-75F4A60F-5214-4E5C-840F-B3E8E41A0779 Q37645090-C7B00F3D-9082-4639-9820-05F31BEB9063 Q37649634-9F13869D-4AD1-4E2E-90A0-EA50AE066547 Q37660260-BF5EE162-FE3E-4348-B903-189A920B4C02 Q37727180-D5B35F94-C1DF-468E-8ABD-91B807933350 Q37880903-1E85D732-D4E1-4DA2-89BE-E57104F93C9E

P2860

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

http://www.wikidata.org/entity/Q34810176

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@ast

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@en

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@nl

type

label

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@ast

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@en

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@nl

prefLabel

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@ast

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@en

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@nl

P1433

Q34810176-8A8437FF-338D-47FF-990F-90A0C1546626

P1476

Q34810176-655FED4F-D5A7-46B1-B958-53F978ABD1C7

P2093

Q34810176-1596D554-BD26-4BF0-8DDD-6FEADA801B53

Q34810176-27DF9846-62AD-4468-AFBE-14707AAE39B9

Q34810176-3466C771-D24B-497A-8698-92D80B7BEB4A

Q34810176-5925F78A-12ED-482C-8220-E516C7F3B51C

Q34810176-8512F2AA-FA75-4D65-BF70-8323B6817F99

Q34810176-99641AE0-9543-40F8-BB8E-BBE405FCED73

Q34810176-C3AC8594-177E-441A-976F-7421B792352D

Q34810176-D8576EAB-EC6F-41A3-9C41-D2E8A2977271

Q34810176-E5E40952-1B28-4CF5-8E80-DBC4326F758B

Q34810176-FF356CA0-4F7C-4B77-A3DD-3F8F0E7BBF31

P2860

Q34810176-067770E8-B5E3-466C-8382-3A399F910EAE

Q34810176-0A4E43E2-1C65-4CA0-A04A-DAC9A0A4F4C9

Q34810176-0B2720E3-A271-4A31-BB6D-C4CAA96069B7

Q34810176-1E8AC785-2BBD-4C36-8C2B-E7B845E08845

Q34810176-1EDD67A2-A110-466E-987C-A92FC0C6CB66

Q34810176-29F7ACCB-8D04-4666-A035-8120335EEF9E

Q34810176-2ACA3F7E-2882-4F31-A2B8-A8F3F0DA239B

Q34810176-2EEF00D0-75EF-4BA7-9693-819AC1E0E51D

Q34810176-2FEC6A3F-DBF0-44F3-BEC5-BBEF27A2CE9F

Q34810176-33FF1E8B-99BB-4D1F-BBB8-D08B9688A002

P304

Q34810176-5E437DCE-6824-46A4-959D-5247EA975927

P31

Q34810176-AB58B168-B84B-45F4-A3E1-B674BF5A963B

P356

Q34810176-3ADC3223-EFEC-4C3E-9164-DA1A3B05381D

P407

Q34810176-70C075C6-2B5A-4403-8204-35767A177CBB

P433

Q34810176-53B50A85-6FD3-40B1-BAD6-1EE55980654E

P478

Q34810176-443D526A-06CB-4928-93FC-55FBFDDC178F

P577

Q34810176-58F7B5DD-8AC1-4AB8-98C5-1A99DF7C787B

P5875

Q34810176-9AD41A1F-0764-4869-BF6D-011EEBF570BD

P698

Q34810176-75DBE2AC-BB3A-446D-BA55-00D5161EF622

P932

Q34810176-21EE17B7-CD4E-4149-A10A-BF27165EEB9E

P356

1078-0432.CCR-10-2289

P1433

Clinical Cancer Research

P1476

Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.

@en

P2093

Amer Karam

http://www.w3.org/2001/XMLSchema#string

Carol Eng

http://www.w3.org/2001/XMLSchema#string

Chintda Santiskulvong

http://www.w3.org/2001/XMLSchema#string

David Mulholland

http://www.w3.org/2001/XMLSchema#string

Gottfried E Konecny

http://www.w3.org/2001/XMLSchema#string

Hong Wu

http://www.w3.org/2001/XMLSchema#string

Kuang-Yui Michael Chen

http://www.w3.org/2001/XMLSchema#string

Min Song

http://www.w3.org/2001/XMLSchema#string

Mirela Fekete

http://www.w3.org/2001/XMLSchema#string

Oliver Dorigo

http://www.w3.org/2001/XMLSchema#string

P2860

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Cancer statistics, 2010

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

P304

2373-2384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2289

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50270950

http://www.w3.org/2001/XMLSchema#string

P698

21372221

http://www.w3.org/2001/XMLSchema#string

P932

3078990

http://www.w3.org/2001/XMLSchema#string